Health Canada Summary Basis of Decision January 19, 2026. Yesintek and Yesintek I.V., 130 mg/26 mL solution (5 mg/mL) ustekinumab, solution, intravenous administration. Also, 45 mg/0.5 mL and 90 mg/1 mL solution, Biosimilar Collaborations Ireland Limited. Submission Control Number 284892
Health Canada Summary Basis of Decision 2026-02-11. Tevimbra, tislelizumab 100 mg/10 mL, solution, BeOne Medicines I GmbH. Submission Control Number 293878
Health Canada Summary Basis of Decision 2026-02-19. Zurzuvae, zuranolone, 20 mg, 25 mg, and 30 mg, capsule, Biogen Canada Inc. Submission Control Number 290103
Health Canada Summary Basis of Decision 2026/02/11. Tyruko, natalizumab, 300 mg/15 mL, solution, Polpharma Biologics S.A. Submission Control Number 286523
Health Canada Summary Basis of Decision 2026-02-02. Ahzantive, 2 mg/0.05 mL aflibercept, solution, Valorum Biologics LLC. Submission Control Number 292152
Health Canada Summary Basis of Decision 2026-02-09. Elfabrio, pegunigalsidase alfa 5 mg/2.5 mL and 20 mg/10 mL, solution, Chiesi Farmaceutici S.p.A. Submission Control Number 287986
Health Canada Summary Basis of Decision 2026-01-19. Enzeevu, aflibercept, 2 mg/0.05 mL (40 mg/mL), solution, Sandoz Canada Inc. Submission Control Number 290401
Health Canada Summary Basis of Decision 2026-01-31. Imaavy, nipocalimab 300 mg/1.62 mL (185 mg/mL) and 1,200 mg/6.5 mL (185 mg/mL), solution, Janssen Inc. Submission Control Number 293081
Health Canada Summary Basis of Decision 2026-02-02. Nilemdo, 180 mg bempedoic acid, tablet, HLS Therapeutics Inc. Submission Control Number 291745
Secretary-General of ASEAN, Dr. Kao Kim Hourn, delivered remarks at a dinner reception held at the Imperial Hotel Tokyo, on 5 March 2026, bringing together Ambassadors of ASEAN Members in Tokyo, members of the Economic Research Institute for ASEAN and East Asia (ERIA) Parliamentary … Continue reading Secretary-General of ASEAN delivers remarks at Dinner Reception with Japanese Partners and StakeholdersASEAN Main Portal
